Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Hematological malignancies require novel therapeutic strategies beyond current treatments.
• Combination therapy offers a promising approach to target cancer cells via multiple mechanisms.
• Virotherapy, using viruses to selectively destroy cancer cells, is an emerging and safe treatment modality.

Purpose of the Study:

• To evaluate the efficacy of the Iraqi strain of Newcastle disease virus (NDV) against hematological tumors.
• To investigate the synergistic effects of NDV in combination with doxorubicin and rituximab.
• To elucidate the role of p53 pathways in the observed synergistic anti-cancer effects.

Main Methods:

• In vitro and in vivo testing of the Iraqi NDV strain.
• Chou-Talalay analysis to assess drug synergy.
• Measurement of p53 concentration to evaluate the mechanism of action.

Main Results:

• NDV demonstrated synergy with low-dose doxorubicin against plasmacytoma cells, with p53 pathway involvement varying by cell type.
• Combination therapy of NDV and rituximab exhibited enhanced cytotoxicity against non-Hodgkin lymphoma cells.
• The synergistic anti-cancer effects were found to be p53-independent in some combinations.

Conclusions:

• The Iraqi strain of NDV shows potential as a component of combination therapy for hematological malignancies.
• NDV combined with doxorubicin or rituximab offers a novel therapeutic strategy with enhanced efficacy.
• Further research into NDV-based combination therapies could lead to improved treatment outcomes for blood cancers.